Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease

Journal of Nuclear Medicine

Volumn 57, Issue 10, 2016, Pages 1535-1542

  Shcherbinin, Sergey ^a   Schwarz, Adam J ^a   Joshi, Abhinay ^b   Navitsky, Michael ^b   Flitter, Matthew ^b   Shankle, William R ^c,d   Devous, Michael D ^b   Mintun, Mark A ^b  

^a ELI LILLY AND COMPANY   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

^c Hoag Neurosciences Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F AV 1451 (T807); Kinetics; Neurology; PET; Radiotracer tissue; Tau; Tracer

Indexed keywords

FLORTAUCIPIR F 18; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; TAU PROTEIN; TRACER;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; BRAIN CORTEX; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; KINETICS; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIOLOGICAL PARAMETERS; SUV RATIO; VOXELWISE BINDING POTENTIAL; YOUNG ADULT; AGED; BIOLOGICAL MODEL; COGNITION; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CARBOLINES; COGNITION; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TAU PROTEINS; YOUNG ADULT;

EID: 84991386848     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.170027     Document Type: Article

References (23)

1. Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD): part I - clinical and neurophysiological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.
2. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's Disease (CERAD): part II - standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
3. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
4. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl). 2006;112:389-404.
5. 11C] PBB3: a new PET ligand that identifies tau pathology in the brains of patients with AD. Nat Rev Neurol. 2013;9:599.
6. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:816-826.
7. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420-1427.
8. 18F-THK-5105 PET. Brain. 2014;137:1762-1771.
9. Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171-184.
10. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666-676.
11. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457-468.
12. Jagust W. Time for tau. Brain. 2014;137:1570-1571.
13. Villemagne VL, Fodero-Tavoletti MT, Masters CL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114-124.
14. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 2011;7:270-279.
15. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 2011;7:263-269.
16. Joshi AD, Pontecorvo MJ, Lu M, et al. A semi-automated method for quantification of florbetapir F 18 PET images. J Nucl Med. September 3, 2015 [Epub ahead of print].
17. Smith S, Bannister P, Beckman C, et al. FSL: new tools for functional and structural brain image analysis. Seventh Int Conf on Functional Mapping of the Human Brain. 2001;106:11-20.
18. Evans AC, Marrett S, Bub D, et al. Anatomical mapping of functional activation in stereotactic coordinate space. Neuroimage. 1992;1:43-53.
19. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-289.
20. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
21. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
22. 11C]-PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
23. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22:1271-1281.